Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2016

View Archived Issues

Data presented on brentuximab vedotin in germ-cell tumors

Daiichi Sankyo divulges new S1PL inhibitors

Aryl-sulfonamides as isoform-selective inhibitors of Nav1.7

A first-in-human study of RG-7666

Allied-Bristol Life Sciences launches new subsidiary iBeCa Therapeutics

Microlin Bio to acquire Marina's nucleic acid therapeutic assets

Mologen announces extension of TEACH study

Vraylar now available in the U.S. as treatment of adults with bipolar mania and schizophrenia

FDA grants breakthrough therapy designation for NI-0501 for the treatment of primary HLH

MP-376 receives QIDP designation

Sanofi and DiCE Molecules announce research collaboration

BioBlast Pharma announces positive final results from HOPEMD phase II study

Istituto Europeo di Oncologia patents KDM1A inhibitors

Synergistic anticancer effects of GEN-1 combined with Avastin and Doxil in preclinical studies

Merck & Co. discloses DGAT-2 inhibitors

AstraZeneca exercises option to acquire rights to Orexo's OX-CLI program

Nippon Shinyaku develops JAK1 inhibitors

TES Pharma presents ACMSD inhibitors

Amgen divulges Mcl-1 inhibitors

Grant supports City of Hope's development of treatment for Canavan disease

Cleveland BioLabs updates progress of entolimod pre-EUA review

MDxHealth launches SelectMDx for Prostate Cancer test in U.S.

Proof of concept achieved in phase IIa trial of VTP-43742 for psoriasis

VESTRI safety study of Advair Diskus in children meets primary endpoint

FDA approves Kovaltry for hemophilia A in children and adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.